Viruses Resistant to Oseltamivir or Baloxavir: What Do the Data Reveal About Resistance?
Publisher
Springer Singapore
Reference30 articles.
1. Takashita E, Daniels RS, Fujisaki S, Gregory V, Gubareva LV, Huang W, et al. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017–2018. Antiviral Res. 2020;175:104718. https://doi.org/10.1016/j.antiviral.2020.104718.
2. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol. 1992;176:119–30. https://doi.org/10.1007/978-3-642-77,011-1_8.
3. Tisdale M. Influenza M2 ion-channel and neuraminidase inhibitors. In: Mayers DL, Lerner SA, Ouellette M, Sobel JD, editors. Antimicrobial drug resistance; clinical and epidemiological aspects. New York: Springer; 2009;421–47. https://doi.org/10.1007/978-1-59745-180-2_31.
4. Cochran KW, Maassab HF, Tsunoda A, Berlin BS. Studies on the antiviral activity of amantadine hydrochloride. Ann N Y Acad Sci. 1965;130(1):432–9. https://doi.org/10.1111/j.1749-6632.1965.tb12579.x.
5. Appleyard G. Amantadine-resistance as a genetic marker for influenza viruses. J Gen Virol. 1977;36(2):249–55. https://doi.org/10.1099/0022-1317-36-2-249.